These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 16390928)

  • 21. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin.
    Koman LA; Paterson Smith B; Balkrishnan R
    Paediatr Drugs; 2003; 5(1):11-23. PubMed ID: 12513103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Botulinum toxin. Development for therapeutic purposes].
    Ceballos-Baumann A
    Nervenarzt; 2008 Jun; 79 Suppl 1():3-8. PubMed ID: 18927957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin treatment of axial and cervical dystonia.
    Benecke R; Dressler D
    Disabil Rehabil; 2007 Dec; 29(23):1769-77. PubMed ID: 18033602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Applications of botulinum toxin in Neurology].
    Garcia-Ruiz PJ
    Med Clin (Barc); 2013 Jul; 141(1):33-6. PubMed ID: 23434466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurotoxins licensed as treatment for neck neuromuscular disorder.
    Am J Health Syst Pharm; 2001 Feb; 58(3):200, 202. PubMed ID: 11217174
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety and self-reported efficacy of botulinum toxin for adult spasticity in current clinical practice: a prospective observational study.
    Muller F; Cugy E; Ducerf C; Delleci C; Guehl D; Joseph PA; Burbaud P; Dehail P
    Clin Rehabil; 2012 Feb; 26(2):174-9. PubMed ID: 21937525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
    Hubble J; Schwab J; Hubert C; Abbott CC
    Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of botulinum toxin in pediatric spasticity (cerebral palsy).
    Berweck S; Heinen F
    Mov Disord; 2004 Mar; 19 Suppl 8():S162-7. PubMed ID: 15027070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States.
    Patil S; Willett O; Thompkins T; Hermann R; Ramanathan S; Cornett EM; Fox CJ; Kaye AD
    Curr Pain Headache Rep; 2016 Mar; 20(3):15. PubMed ID: 26879873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding Clinical Effectiveness and Safety Implications of Botulinum Toxin in Children: A Narrative Review of the Literature.
    Crisafulli S; Ciccimarra F; Khan Z; Maccarrone F; Trifirò G
    Toxins (Basel); 2024 Jul; 16(7):. PubMed ID: 39057946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical use of botulinum toxin].
    Jost WH
    Nervenarzt; 2008 Jun; 79 Suppl 1():9-14. PubMed ID: 18927958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Botulinum toxins: pharmacology and its current therapeutic evidence for use.
    Panicker JN; Muthane UB
    Neurol India; 2003 Dec; 51(4):455-60. PubMed ID: 14742921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Botulism toxin in practice].
    Durand A; Serment G
    Ann Readapt Med Phys; 2003 Jul; 46(6):386-8. PubMed ID: 12928147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botox: beyond wrinkles.
    Carruthers J; Carruthers A
    Clin Dermatol; 2004; 22(1):89-93. PubMed ID: 15158551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.
    Luvisetto S; Gazerani P; Cianchetti C; Pavone F
    Toxins (Basel); 2015 Sep; 7(9):3818-44. PubMed ID: 26404377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Botulinum toxin: a dreaded toxin for use in human being.
    Ghosh B; Das SK
    J Indian Med Assoc; 2002 Oct; 100(10):607-8, 610-2, 614. PubMed ID: 12452515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Commentary: Botulinum toxin in clinical medicine: part II.
    Benedetto AV
    Clin Dermatol; 2004; 22(1):1-2. PubMed ID: 15158537
    [No Abstract]   [Full Text] [Related]  

  • 39. Botulinum toxin type B (Myobloc).
    Baumann L; Black L
    Dermatol Surg; 2003 May; 29(5):496-500; discussion 500. PubMed ID: 12752517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical value of botulinum toxin in neurological indications.
    Ward AB; Molenaers G; Colosimo C; Berardelli A
    Eur J Neurol; 2006 Dec; 13 Suppl 4():20-6. PubMed ID: 17112346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.